Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 6/2013

01.12.2013 | Hot Topic

Uric Acid, Hypertension, and Cardiovascular and Renal Complications

verfasst von: Carmine Zoccali, Francesca Mallamaci

Erschienen in: Current Hypertension Reports | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Over the last decade, the biologic interference of uric acid with the cardiovascular (CV) system and the kidney has been intensively investigated, and several experimental studies in animal models and in vitro documented that hyperuricemia may trigger hypertension and incite endothelial dysfunction, vascular damage and renal disease. A substantial proportion of epidemiological studies are compatible with the hypothesis that hyperuricemia may be noxious to the CV system and the kidney as well. However, there are still no well-powered trials testing whether uric acid–lowering interventions may reduce BP or attenuate the risk for adverse CV and renal outcomes. Evidence still remains largely insufficient to recommend changes in the current policy of not prescribing uric acid–lowering drugs to individuals with asymptomatic hyperuricemia.
Literatur
1.
Feig DI. Hyperuricemia and hypertension. Adv Chronic Kidney Dis. 2012;19:377–85. A comprehensive review of the link between hyperuricemia and hypertension.PubMedCrossRef
2.
Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for CV disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7–13.PubMedCrossRef
3.
Moritz AR, Oldt MR. Arteriolar sclerosis in hypertensive and non-hypertensive individuals. Am J Pathol. 1937;13:679–728.PubMed
4.
Walker MB, Boyd GW. The distribution of arteriolosclerosis along the arterioles in DOCA hypertensive rats. Clin Exp Pharmacol Physiol. 1983;10:319–23.PubMedCrossRef
5.
Sumpio BE, Widmann MD, Ricotta J, et al. Increased ambient pressure stimulates proliferation and morphologic changes in cultured endothelial cells. J Cell Physiol. 1994;158:133–9.PubMedCrossRef
6.
Hishikawa K, Nakaki T, Marumo T, et al. Pressure promotes DNA synthesis in rat cultured vascular smooth muscle cells. J Clin Invest. 1994;93:1975–80.PubMedCrossRef
7.
Lombardi D, Gordon KL, Polinsky P, et al. Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Hypertension. 1999;33:1013–9.PubMedCrossRef
8.
Quiroz Y, Pons H, Gordon KL, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Ren Physiol. 2001;281:F38–47.
9.
Sanchez-Lozada LG, Tapia E, Jimenez A, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Ren Physiol. 2007;292:F423–9.CrossRef
10.
Aida Y, Shibata Y, Osaka D, et al. The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study. Int J Med Sci. 2011;8:470–8.PubMedCrossRef
11.
Nieto FJ, Iribarren C, Gross MD, et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131–9.PubMedCrossRef
12.
Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269–75.PubMedCrossRef
13.
Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41:1287–93.PubMedCrossRef
14.
Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553–62.PubMedCrossRef
15.
Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266:8604–8.PubMed
16.
Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12:1434–47.PubMed
17.
Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67:237–47.PubMedCrossRef
18.
Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346:913–23.PubMedCrossRef
19.
Hsu CH, Patel SR, Young EW, Vanholder R. Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol. 1991;260:F596–601.PubMed
20.
Sigmund CD. Regulation of renin expression and blood pressure by vitamin D(3). J Clin Invest. 2002;110:155–6.PubMed
21.
Vanholder R, Patel S, Hsu CH. Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure. J Am Soc Nephrol. 1993;4:1035–8.PubMed
22.
Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Ren Physiol. 2002;282:F991–7.
23.
Mori T, Cowley Jr AW. Role of pressure in angiotensin II-induced renal injury: chronic servo-control of renal perfusion pressure in rats. Hypertension. 2004;43:752–9.PubMedCrossRef
24.
Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–42.PubMedCrossRef
25.
Waring WS, Adwani SH, Breukels O, et al. Hyperuricaemia does not impair CV function in healthy adults. Heart. 2004;90:155–9.PubMedCrossRef
26.
Zoccali C, Maio R, Mallamaci F, et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006;17:1466–71.PubMedCrossRef
27.
Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation. 2004;110:821–5.PubMedCrossRef
28.
Johnson RJ, Rodriguez-Iturbe B, Kang DH, et al. A unifying pathway for essential hypertension. Am J Hypertens. 2005;18:431–40.PubMedCrossRef
29.
Kahn HA, Medalie JH, Neufeld HN, et al. The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J. 1972;84:171–82.PubMedCrossRef
30.
Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary artery risk development in (Young) adults. J Hum Hypertens. 1999;13:13–21.PubMedCrossRef
31.
Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: the Osaka health survey. J Hypertens. 2001;19:1209–15.PubMedCrossRef
32.
Imazu M, Yamamoto H, Toyofuku M, et al. Hyperinsulinemia for the development of hypertension: data from the Hawaii-Los Angeles-Hiroshima study. Hypertens Res. 2001;24:531–6.PubMedCrossRef
33.
Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–80.PubMedCrossRef
34.
Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523–30.PubMedCrossRef
35.
Nagahama K, Inoue T, Iseki K, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27:835–41.PubMedCrossRef
36.
Rovda I, Kazakova LM, Plaksina EA. Parameters of uric acid metabolism in healthy children and in patients with arterial hypertension. Pediatriia. 1990;8:19–22.
37.
Torok E, Gyarfas I, Csukas M. Factors associated with stable high blood pressure in adolescents. J Hypertens Suppl. 1985;3:S389–90.PubMed
38.
Goldstein HS, Manowitz P. Relation between serum uric acid and blood pressure in adolescents. Ann Hum Biol. 1993;20:423–31.PubMedCrossRef
39.
Nefzger MD, Acheson RM, Heyman A. Mortality from stroke among U.S. veterans in Georgia and 5 western states. I. Study plan and death rates. J Chronic Dis. 1973;26:393–404.PubMedCrossRef
40.
Saito I, Folsom AR, Brancati FL, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med. 2000;133:81–91.PubMedCrossRef
41.
Staessen J. The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. Am J Med. 1991;90:50S–4S.PubMedCrossRef
42.
Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol. 2000;10:136–43.PubMedCrossRef
43.
Alper Jr AB, Chen W, Yau L, et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension. 2005;45:34–8.PubMedCrossRef
44.
Sundstrom J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33.PubMedCrossRef
45.
46.
Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69:1418–23.
47.
Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for CV and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546–51.PubMedCrossRef
48.
Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997;78:147–53.PubMed
49.
Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005 Mar;2(3):e76.
50.
Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37:1503–7.PubMedCrossRef
51.
Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and CV disease: recent developments, and where do they leave us? Am J Med. 2005;118:816–26.PubMedCrossRef
52.
Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–7.PubMedCrossRef
53.
Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant. 2010;25:1865–9.PubMedCrossRef
54.
Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010;33:1337–43.PubMedCrossRef
55.
Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19:1204–11.PubMedCrossRef
56.
Obermayr RP, Temml C, Knechtelsdorfer M, et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant. 2008;23:1265–73.PubMedCrossRef
57.
Bellomo G, Venanzi S, Verdura C, et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56:264–72.PubMedCrossRef
58.
Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53:796–803.PubMedCrossRef
59.
Sturm G, Kollerits B, Neyer U, et al. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43:347–52.PubMedCrossRef
60.
Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15:34–42.PubMedCrossRef
61.
• Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479–85. A large observational study linking uric acid levels and progression to end stage renal diseae in IgA nephropathy.PubMedCrossRef
62.
• Helal I, McFann K, Reed B, et al. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013;28:380–5. A study suggesting that high serum uric acid may be involved in renal function loss in ADPPKD.PubMedCrossRef
63.
Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009 Jun;5(6):e1000504.
64.
Testa A, Leonardis D, Catalano F, et al. The SLC2A9 polymorphism, the major genetic determinant of serum uric acid levels, predicts progression to kidney failure in CKD patients. (Abstract SAP014). Presented at the 49th ERA-EDTA Congress, Paris, France; May 24-27, 2012.
65.
Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int. 2004;66:281–7.PubMedCrossRef
66.
Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924–32.PubMedCrossRef
67.
Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227–33.PubMedCrossRef
68.
Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.PubMedCrossRef
69.
Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and CV risk. Clin J Am Soc Nephrol. 2010;5:1388–93.PubMedCrossRef
70.
Dahlof B, Devereux RB, Kjeldsen SE, et al. CV morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRef
71.
Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22:1382–9.PubMedCrossRef
72.
•• Rekhraj S, Gandy SJ, Szwejkowski BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61:926–32. A randomized double-blinded, placebo controlled trial (RCT) showing that allopurinol at the dose of 800 mg/d reduces left ventricular hypertrophy and arterial stiffness in patients with coronary heart disease. This trial fully confirms findings in a previous RCT in CKD patients (Ref.71).PubMedCrossRef
73.
Okin PM, Devereux RB, Jern S, et al. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. Am J Hypertens. 2001;14:775–82.PubMedCrossRef
Metadaten
Titel
Uric Acid, Hypertension, and Cardiovascular and Renal Complications
verfasst von
Carmine Zoccali
Francesca Mallamaci
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 6/2013
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-013-0391-y

Weitere Artikel der Ausgabe 6/2013

Current Hypertension Reports 6/2013 Zur Ausgabe

Preeclampsia (VD Garovic, Section Editor)

Proteinuria in Preeclampsia from a Podocyte Injury Perspective

Hypertension and the Brain (M Banach and A Zanchetti, Section Editors)

Hypertension, Brain Damage and Cognitive Decline

Prevention of Hypertension: Public Health Challenges (P Muntner, Section Editor)

Physical Activity and the Prevention of Hypertension

Pulmonary Hypertension (Z-C Jing, Section Editor)

A GPS Map for Pulmonary Hypertension: A Review of Imaging Modalities

Prevention of Hypertension: Public Health Challenges (NK Hollenberg, Section Editor)

Association Between Pre-hypertension and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Prospective Studies

Hypertension and the Brain (M Banach and A Zanchetti, Section Editors)

Neurogenic and Sympathoexcitatory Actions of NaCl in Hypertension

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise